Midostaurin, an inhibitor of several Type III tyrosine kinase receptors, is approved for newly diagnosed adult patients with FLT3-mutated AML and advanced systemic mastocytosis (SM) [17, 18], especially MCL with KIT D816 mutations [10]. This evidence concerns the gene FLT3 and systemic mastocytosis.